Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2024 | $6.00 | Buy | BTIG Research |
| 10/3/2023 | $10.00 | Overweight | CapitalOne |
| 7/6/2023 | $12.00 | Outperform | Evercore ISI |
| 5/31/2023 | $0.60 → $7.00 | Hold → Buy | Jefferies |
| 5/24/2023 | $10.00 | Buy | H.C. Wainwright |
| 4/14/2023 | $10.00 | Outperform | Robert W. Baird |
New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical effic
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (NASDAQ:MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD - The Liver Meeting ® 2024 Cash and cash equivalents of $26.9 million expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Nov. 7, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biophar
BTIG Research initiated coverage of Carisma Therapeutics with a rating of Buy and set a new price target of $6.00
CapitalOne initiated coverage of Carisma Therapeutics with a rating of Overweight and set a new price target of $10.00
Evercore ISI initiated coverage of Carisma Therapeutics with a rating of Outperform and set a new price target of $12.00
10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508. The termination is effective July 31, 2024. Pursuant to the Company’s revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508. As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the thir
Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna. What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna. The development candidate leverages Carisma’s expertise in engineering chimeric antigen receptor monocytes and macrophages (CAR-M) with Moderna’s mRNA and lipid nanoparticle platform. This collaboration aims to create novel in vivo cell therapies for onco
PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | Trump Media & Technology Group shares are trading higher following Thursday's presidential debate. CARM: 95% | Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
3 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting New preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD - The Liver Meeting ® 2024 Cash and cash equivalents of $26.9 million expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Nov. 7, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biophar
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA, Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments. "It's a pleasure to we
Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA, Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focus